ArticleAnalytical chemistry2025
Early Detection of Multiple Sclerosis Using Spectroscopic Epstein-Barr Virus Biosensors Based on Infection Mechanism Mimicry.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between Epstein-Barr virus (EBV) and multiple sclerosis has made the asymptomatic detection of EBV very significant. In this study, a spectroscopic/colorimetric EBV biosensor was developed for practical and early screening by replicating the virus's natural infection mechanism. In order to accomplish this, gold nanoparticles (AuNPs) were functionalized with the B cell surface protein CD21, thereby mimicking the native host cell receptor. The interaction between CD21@AuNP and the EBV surface glycoprotein gp350 was then obtained spectroscopically through absorbance measurements, which was accompanied by a visible color change. Experimental parameters, including the incubation temperature and time, were systematically optimized to enhance the assay performance. Under optimized conditions, the biosensor exhibited a linear detection range of 10-100 ng/mL, with a limit of detection of 0.0279 ng/mL, a limit of quantification of 0.0848 ng/mL, and a relative standard deviation of 0.848%. Validation with 1:100 diluted saliva samples obtained from healthy volunteers further confirmed the sensor's high sensitivity and robustness, demonstrating its strong potential for translation into real-world diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.